Ionis Pharma's Q3 revenue beats expectations, raises guidance

Ionis Pharmaceuticals

29/10/2025 11:14

Overview

Ionis Q3 2025 revenue grows 17% yr/yr, beating analyst expectations

Adjusted EPS for Q3 2025 beats consensus, reflecting strong operational performance

Company raises 2025 financial guidance due to strong revenue performance

Outlook

Ionis raises 2025 revenue guidance to $875-900 mln from $825-850 mln

TRYNGOLZA 2025 sales guidance increased to $85-95 mln from $75-80 mln

Ionis expects cash flow breakeven by 2028

Result Drivers

TRYNGOLZA SALES - Nearly 70% increase in TRYNGOLZA sales over the prior quarter, contributing to revenue growth

ROYALTY REVENUE - Higher royalty revenue contributed to year-over-year revenue increase

UPFRONT PAYMENT - $280 mln upfront payment from Ono Pharmaceutical for sapablursen license boosted revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$157 mln
$130.92 mln (18 Analysts)
Q3 EPS
Beat
-$0.80
-$1.23 (17 Analysts)
Q3 Net Income
-$129 mln
Q3 Adjusted Operating Income
Beat
-$129 mln
-$196.11 mln (17 Analysts)
Q3 Adjusted Operating Expenses
$286 mln
Q3 Operating Expenses
$317 mln
Q3 Operating Income
-$160 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Ionis Pharmaceuticals Inc is $78.00, about 5.7% above its October 28 closing price of $73.57

Press Release: ID:nBw3GWZvTa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)